Krystal Biotech, Inc.
KRYS
Ранг среди акций
#2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Цена акции
$326.41
Рыночная капитализация
$9.66B
Изменение (1 день)
1.92%
Изменение (1 год)
66.57%
Страна
US
Торговля Krystal Biotech, Inc. (KRYS)
Категория
Healthcare
История дроблений акций Krystal Biotech, Inc. (KRYS)
Акции Krystal Biotech, Inc. (символ: KRYS) прошли через 0 дроблений.
Последнее дробление произошло Oct 20, 2026.
Одна акция KRYS, купленная до Oct 20, 2026, сейчас соответствует 0 акциям KRYS.
Последнее дробление произошло Oct 20, 2026.
Одна акция KRYS, купленная до Oct 20, 2026, сейчас соответствует 0 акциям KRYS.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| Недостаточно данных для указанных дат. | |||
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|